Gregory Ortega, MD
Hematology & Oncology · Orange City, FLNPI 1720037989
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $10,812 of the $11,400 with a category attached, or 94.8%. Tosoh Bioscience, Inc. accounts for 94.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $11,204 and has fallen 99.6% since, to $39 in 2024.
Across 19 payments — averaging $599.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tosoh Bioscience, Inc.$11K
- Seagen Inc.$187
- Takeda Pharmaceuticals U.S.A., Inc.$99
- Johnson & Johnson$85
- E.r. Squibb & Sons, L.L.C.$54
- Exelixis Inc.$48
- plus $115 from 5 others
Across 2 payments — averaging $3179.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Apellis Pharmaceuticals, Inc.$4K
- Bristol Myers Squibb$3K
What the payments were for
- Food & beverage$3893%
- Education$1982%
- Gifts$10,81295%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tosoh Bioscience, Inc. | 4 | $10,812 |
| Seagen Inc. | 2 | $187 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $99 |
| Johnson & Johnson | 1 | $85 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Exelixis Inc. | 1 | $48 |
| Gilead | 1 | $33 |
| AstraZeneca | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| AbbVie | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOL, AIA-PACK, Calibrator Set$5,406
- ST AIA-PACK Cystatin C Calibrator Set$5,406
- TSH3G, AIA-PACK Calibrator Set$2,703
- CA19-9, ST AIA-PACK$2,703
- CA 19-9, Sample Diluting Solution$2,703
- B12, AIA-PACK$2,703
- PA, ST AIA-PACK$2,703
- PA, AIA-PACK Calibrator Set$2,703
- CEA, ST, AIA-PACK$2,703
- CEA, AIA-PACK Calibrator Set$2,703
- TSH, ST AIA-PACK$2,703
- CEA, AIA-PACK Linearity Set$2,703
- PA, AIA-PACK Linearity Set$2,703
- Cystatin C, ST AIA-PACK$2,703
- B12, AIA-PACK Calibrator Set$2,703
- B12, AIA-PACK Sample Diluting Solution$2,703
- FOL, AIA-PACK$2,703
- FOL, AIA-PACK, Sample Diluting Solution$2,703
- PADCEV$102
How this compares
$11,400 in reported general payments places this provider in the 65th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 12 | $474,478 |
| ReblozylLuspatercept-Aamt | 23 | $432,600 |
| BrukinsaZanubrutinib | 24 | $342,721 |
| PomalystPomalidomide | 11 | $248,131 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 22 | $227,618 |
| ErleadaApalutamide | 13 | $224,182 |
| ImfinziDurvalumab | 19 | $216,950 |
| VerzenioAbemaciclib | 11 | $165,383 |
| KeytrudaPembrolizumab | 12 | $136,072 |
| PerjetaPertuzumab | 17 | $111,523 |
| Everolimus | 12 | $108,421 |
| TrazimeraTrastuzumab-Qyyp | 23 | $105,548 |
| ProcritEpoetin Alfa | 46 | $103,543 |
| EliquisApixaban | 100 | $83,858 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $74,970 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Reblozyl, Pomalyst | $54 | $680,73134 claims |
| Johnson & JohnsonErleada, Procrit, Xarelto | $85 | $352,63981 claims |
| AstraZenecaImfinzi | $23 | $216,95019 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $99 | $74,97011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Orange City
- Neeraj SharmaOrange City$121K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.